比较慢性乙型肝炎治疗间肝细胞癌风险的荟萃分析方法学挑战
本文综述了比较恩替卡韦与富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎患者肝细胞癌风险的荟萃分析存在的方法学问题。争议部分源于显著性水平的任意性导致相似数据集得出矛盾结论,观察性数据的异质性及两种药物在东亚异步上市也增加不确定性。建议研究者和读者关注观察性研究及荟萃分析的质量。
要点
- 恩替卡韦与替诺福韦比较肝细胞癌风险的荟萃分析结论矛盾,部分因显著性水平任意性。
- 观察性数据存在患者特征的研究内和研究间异质性,增加不确定性。
- 两种药物在东亚异步上市导致随访时间差异,进一步复杂化分析。
核心结论
- 比较恩替卡韦与替诺福韦治疗慢性乙型肝炎患者肝细胞癌风险的荟萃分析结论仍存争议,方法学决策和纳入研究质量是关键限制因素。
研究设计与样本
- 本文为综述,旨在帮助临床医生理解已发表的关于慢性乙型肝炎治疗与肝细胞癌风险的荟萃分析,并为未来研究提供建议。
主要发现
- 显著性水平的任意性可导致相似数据集得出矛盾结论。
- 观察性数据存在患者特征的研究内和研究间异质性。
- 恩替卡韦和替诺福韦在东亚异步上市导致随访时间差异,复杂化分析。
临床怎么用
- 临床医生在解读相关荟萃分析时,应关注纳入观察性研究的患者特征、研究设计和统计方法学质量。
- 研究者开展此类荟萃分析时需做方法学决策以减轻偏倚,但受限于纳入研究本身的方法。
局限性
- 荟萃分析方法学受限于所纳入观察性研究的质量和方法。
- 观察性数据固有的异质性和药物上市时间差异难以完全消除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite several recent meta-analyses on the topic, the comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B (CHB) receiving entecavir (ETV) or tenofovir disoproxil fumarate (TDF) remains controversial. The controversy partly results from the arbitrary nature of significance levels leading to contradictory conclusions from very similar datasets. However, the use of observational data, which is prone to both within- and between-study heterogeneity of patient characteristics, also lends additional uncertainty. The asynchronous introduction of ETV and TDF in East Asia, where the majority of these studies have been conducted, further complicates analyses, as does the ensuing difference in follow-up time between ETV and TDF cohorts. Researchers conducting meta-analyses in this area must make many methodological decisions to mitigate bias but are ultimately limited to the methodologies of the included studies. It is therefore important for researchers, as well as the audience of published meta-analyses, to be aware of the quality of observational studies and meta-analyses in terms of patient characteristics, study design and statistical methodologies. In this review, we aim to help clinicians navigate the published meta-analyses on this topic and to provide researchers with recommendations for future work.
引用
- Choi WM, Yip TC, Lim YS, et al. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol. 2021. PMID: 34592365. doi:10.1016/j.jhep.2021.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。